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Pancreatic islet 
macroencapsulation using 
microwell porous membranes
Katarzyna Skrzypek1, Milou Groot Nibbelink2, Jéré van Lente  2, Mijke Buitinga3,  
Marten A. Engelse4, Eelco J. P. de Koning4,5, Marcel Karperien2, Aart van Apeldoorn2,6 & 
Dimitrios Stamatialis  1
Allogeneic islet transplantation into the liver in combination with immune suppressive drug therapy 
is widely regarded as a potential cure for type 1 diabetes. However, the intrahepatic system is 
suboptimal as the concentration of drugs and nutrients there is higher compared to pancreas, which 
negatively affects islet function. Islet encapsulation within semipermeable membranes is a promising 
strategy that allows for the islet transplantation outside the suboptimal liver portal system and 
provides environment, where islets can perform their endocrine function. In this study, we develop 
a macroencapsulation device based on thin microwell membranes. The islets are seeded in separate 
microwells to avoid aggregation, whereas the membrane porosity is tailored to achieve sufficient 
transport of nutrients, glucose and insulin. The non-degradable, microwell membranes are composed 
of poly (ether sulfone)/polyvinylpyrrolidone and manufactured via phase separation micro molding. 
Our results show that the device prevents aggregation and preserves the islet’s native morphology. 
Moreover, the encapsulated islets maintain their glucose responsiveness and function after 7 days of 
culture (stimulation index above 2 for high glucose stimulation), demonstrating the potential of this 
novel device for islet transplantation.
Type 1 diabetes is an autoimmune disorder, characterized by the specific destruction of insulin-producing β-cells 
within the islets of Langerhans, resulting in an absolute insulin deficiency. Currently, type 1 diabetes accounts for 
5–10% of the total cases of diabetes worldwide, occurring mainly in children and young adults1. In fact, more than 
500 000 children under 15 years of age were diagnosed with type 1 diabetes in 20152. Although insulin therapy is 
effective in regulating the blood glucose levels, it still lacks the precise glycemic control that the normal physio-
logical system has. Therefore, it results often in hypoglycemic events, while in the long term micro/macrovascular 
complications affect many patients3.
The replacement of β-cells by intrahepatic islet transplantation in combination with immunosuppressive 
drugs can restore insulin independence. However, while often successful, intrahepatic islet transplantation is 
associated with a high degree of islet loss, due to a multifactorial response involving an immediate blood medi-
ated inflammatory response, auto and alloimmunity, and loss of innervation and vascularization4. In addition, 
life-long immune suppressive therapy is necessary resulting in increased risks of attacking infections or certain 
cancers, while the supply of high quality donor pancreas available for islet isolation and transplantation is very 
limited. Encapsulation using biomaterials, to provide a physical barrier between transplanted β-cells and their 
recipients, has emerged as a promising approach to improve transplantation outcomes eliminating the need for 
immunosuppression4, 5. Moreover, encapsulation could allow for using of not only human donor islets, but also 
the use of de novo beta cells derived from stem cells, or even xenogeneic islets and help overcome the islet donor 
shortage limitations.
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Commonly applied strategies often focus on encapsulation of single islets using either hydrogels, or 
nanometer-scale coatings, such as, alginate, polyethylene glycol, polylactide-derived, or cation-anion layer by 
layer systems6–8. Although, initial results suggest that islets can maintain their function, long-term survival can-
not be guaranteed. Hydrogels are, in most cases, not stable enough to support islets transplantation over long 
time. In recent years, the creation of alternative transplantation sites using three-dimensional scaffolds has been 
explored, too. Highly porous scaffolds such as poly(lactide-glycolide) sponge, vicryl or, poly(glycolic-acid) fibers 
meshes, with high interconnectivity have been proposed as suitable islet encapsulation devices9–11. Islets seeded 
into the macropores of these constructs can easily and quickly be provided with oxygen and the necessary nutri-
ents. However, in most cases these constructs have large pores that permit tissue ingrowth and cell penetration. 
Therefore, this approach still requires the use of immunosuppressive drugs.
The main advantage of macroencapsulation technique is the control of confining the islets to one location 
in the body as well as the ability to retrieve the device and the possibility of islet replenishment, if necessary. 
However, islet encapsulation remains a difficult challenge because, by preventing cytotoxic T-lymphocyte inter-
action with the allogeneic beta cells, the mass transport of necessary nutrients, glucose and insulin is often 
compromised.
A variety of different macroencapsulation designs have been studied such as tubular chambers, sealed hollow 
fibers and planar devices12. However, poor oxygen and nutrient diffusion across the membranes was the main 
reason for eventual graft failure, leading to compromised islet viability. Additionally, the lack of physical sepa-
ration of the islets in these macroencapsulation devices causes aggregation of the islets. This negatively affects 
islet structure, leading to limited diffusion of nutrients and oxygen, loss of function and apoptosis. Jiang et al. 
developed agarose hydrogel membranes with microwell patterns allowing for cells separation as a model encapsu-
lation system13. Moreover, they suggested that micropatterned encapsulation systems may be able to minimize the 
transplantation volume, increase the encapsulation efficiency and improve the cell viability. However, the design 
of an immune protective macroencapsulation device for islets, should strike a balance between optimal survival 
of islets and shielding the same islets from the immune system.
In this study, we propose a novel concept for a macroencapsulation device in which islets are confined between 
two porous membranes. One membrane consists of microwells in which the islets are seeded and the other mem-
brane acts as a lid, see Fig. 1. For both, the microwell and the lid membranes, the porosity is tailored to permit 
nutrient inflow and metabolite outflow, but protects the islets from immune cells. The microwell array allows 
good islet separation and prevents both spreading and aggregation, maintaining the islet’s rounded morphology.
In earlier studies, we developed open microwell scaffolds for vessel ingrowth using poly(ethylene oxide tere-
phthalate)-poly(butylene terephthalate) (PEOT/PBT) biodegradable polymers14. Our aim here is to achieve a 
non-degradable functional closed encapsulation device. Therefore a closed porous system is developed using poly 
(ethersulfone) (PES)/polyvinyl pyrrolidone (PVP) polymer blend via phase separation micromolding, which is a 
unique method for preparation of porous microstructured membranes in one step15–17. PES is a non-degradable 
material that has high stability and good mechanical properties, and is widely used as a membrane material for 
blood purification and other biomedical membrane applications. Blending PES with PVP results in more hydro-
philic membranes that have low fouling and, importantly for islet encapsulation, low cell adhesion properties. The 
porosity of the PES/PVP microwell membranes is tailored to allow insulin and glucose transport and the device 
performance is evaluated by analyzing the glucose responsiveness of encapsulated MIN6 mouse insulinoma cell 
aggregates and of human islets. Our results indicate that the PES/PVP microwell membrane, as a crucial part of 
macroencapsulation device, is a potential carrier for extrahepatic islet transplantation.
Results
Microwell structured membranes fabrication and characterization. We used phase separation 
micromolding to fabricate uniform, porous, microstructured flat membranes. A custom designed mold allowed 
the formation of structures of defined shape and size. Figure 2 shows flat PES/PVP membranes with microwells of 
Figure 1. A schematic overview of the PES/PVP flat membrane encapsulation device.
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excellent quality. The microwells are homogenously distributed over the membrane, reflecting the features of the 
mold used for casting. Each well has 500 µm diameter and 400 µm depth in order to fit a range of pancreatic islets18. 
The cross-section of the membrane presents asymmetric pore morphology. A dense selective layer containing 
small pores (1–3 µm) is present on the bottom of the microwell membrane and provides protection from cell 
infiltration towards the microwells. A finger-like, porous sub-layer, with pores of less than 10 µm, is formed 
between the microwell structures and the top of the selective layer (Fig. 2B). This microwell array allows for good 
separation of the islets, preventing aggregation and spreading which could cause further transport limitation14. 
The islets do not adhere to the PES-based membranes due to its tailored hydrophilicity by addition of PVP. 
Therefore, their rounded morphology is preserved after prolonged culture (Fig. 2C and D). The number of the 
microwells determine the number of the islets possible for encapsulation in order to maintain their viability and 
function. Higher number of islets than the number of available wells used for encapsulation leads to transport 
limitation, thereby decreasing the functionality of the islets. Here, considering the number of wells, we could 
encapsulate 150 islets using 8 mm microwell membrane.
Figure 3A and B present the clean water fluxes (CWF) of the membranes at various transmembrane pressures. 
In all cases, the graph is linear indicating high stability of the membranes in this pressure range. Table 1 presents 
the water hydraulic permeability of all prepared membranes. When reducing the membrane thickness from 250 
to 100 µm, the hydraulic permeability increases from 479 to 668 L/m2/h/bar. Additionally, treatment with NaClO 
solution known for partial removal of PVP from the membrane pores further improves membrane permeability. 
In fact, the hydraulic permeability of the membranes treated with NaClO for two hours is more than double 
compared to the untreated membrane. Longer treatment, namely for 24 hours, results in even higher hydraulic 
permeability of 3845 L/m2/h/bar.
The important requirement for the microwell membrane to be suitable for islet encapsulation is having high 
insulin and glucose permeability. To test this, MIN6 aggregates consisting of 250 cells per aggregate were seeded 
in the microwell membranes assembled in the transwell system and exposed to 16.7 mM glucose solution in 
the bottom compartment. Over time, glucose diffusing through the membrane to the top compartment induces 
insulin secretion from the aggregates. Figure 3C shows that within 10 min the aggregates release insulin, which 
diffuses through the membrane to the bottom compartment. After one hour, the insulin concentration in the 
bottom compartment increases further. Based on these data, the estimated diffusion coefficients of insulin and 
glucose through the membranes are 0.3 × 10–10 and 3.6 × 10−10 m2/s respectively and they are in the same order 
of magnitude as the free diffusion coefficient of the molecules in solution, namely 1.5 × 10−10 m2/s for insulin 
and 9.59 × 10−10 m2/s for glucose. These results indicate that the porosity of microwell membranes is sufficient to 
achieve high transport of insulin and glucose without transport limitations.
Figure 2. Scanning electron microscopy images of microwell membranes. (A) Top view, (B) Cross section, (C) 
Human islets inside the well, (D) MIN6 aggregates inside the well.
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In summary, we successfully fabricated microwell membranes suitable for our encapsulation device. The 
membrane performance was assessed further regarding the functionality of the pancreatic beta cell line MIN6 
aggregates in an open system.
MIN6 aggregates function using open system. A glucose induced insulin secretion test (GIIST) was 
performed for the MIN6 aggregates seeded on the microwell membranes placed in the transwell system. Figure 4 
compares the stimulation index of the aggregates within the microwell membranes to the free-floating aggregates, 
our positive control. For the estimation of the stimulation index, the insulin secretion of all samples was normal-
ized to the insulin secretion of the first experiment of low glucose stimulation. Therefore, in all results presented 
here, the stimulation index of the first low is always equal to one.
In all cases, free-floating aggregates function well (stimulation index more than 2 for high glucose concentra-
tion) and show a clear response to glucose concentration changes. The insulin concentration was analyzed sepa-
rately on the top and bottom compartments of the open microwell system with M1 and M2 membranes (Fig. 4A). 
The MIN6 aggregates on the top compartment respond to glucose concentration changes. Additionally, when 
more open, M2 membrane is used, the insulin concentration in the bottom compartment reaches a similar value 
to the one detected in the top compartment, where cells were in direct contact with the high glucose concentra-
tion solution. Finally, a function test of MIN6 aggregates over 5 h was performed in an open system, using the 
most permeable, 250 µm thick membranes – M3 (Fig. 4B). An increase in insulin release following stimulation, 
compared to basal insulin release levels, was observed there, although statistically different than the response of 
the free-floating aggregates.
Figure 3. Transport characteristics. (A) Clean water flux vs. pressure for 250 µm thick membranes, (B) Clean 
water flux vs. pressure for 100 µm thick membranes, (C) MIN6 aggregates insulin secretion through the 
membrane in response to a high glucose concentration. Error bars indicate standard deviation (n = 3).
Microwell 
membrane
Membrane 
thickness [µm]
Sodium hypochlorite 
treatment [h]
Water hydraulic permeability 
(n = 3) [L/m2/h/bar]
M1 250 — 479 ± 9
M2 250 2 1020 ± 14
M3 250 24 2461 ± 39
M4 100 — 668 ± 17
M5 100 24 3845 ± 33
Table 1. Membrane water permeability.
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In summary, we showed here the development of an optimized functional microwell membrane open system 
where the MIN6 aggregates within the wells respond to glucose concentration changes. The M3 membrane will 
be investigated in the next section as part of a closed system for human islet encapsulation.
Human islet viability and functionality using closed system. Human islets were seeded in the closed 
system with the M3 microwell membrane and cell survival was studied after one day of culture. Figure 5A shows 
that the islets are viable in the closed system, as represented by the green viable cells. As all the encapsulated islets 
were distributed between the wells and their size was smaller than the diameter of the well, designed to fit islets up 
to 500 µm, we observed in some wells small groups consisting few islets. However, these islets could freely move 
within the wells indicating that their aggregation was avoided.
We also investigated the islet function in our closed system consisting of microwell membrane covered with 
a flat PES membrane as a lid. We compared flat membranes with various pore sizes used on the top of the most 
permeable 250 µm (M3) and 100 µm (M5) thick microwell membranes. Figure 5B compares the insulin concen-
tration obtained after glucose stimulation secreted from free-floating islets and islets encapsulated in the closed 
system. Both free-floating and encapsulated islets respond to glucose concentration changes. Islets encapsulated 
in closed system with the thin M5 microwell membrane respond over 5 h in similar manner to free-floating islets 
regardless of the porosity of the lid. However, for the thicker, M3, microwell membrane a lid with pore size of 5 µm 
is required to achieve sufficient glucose transport and obtain better insulin secretion, although significantly lower 
than for free-floating islets (p < 0.05). Since a membrane lid with 0.4–0.45 µm pore size is expected to provide 
sufficient barrier between the islets and recipient’s tissue from the top of the construct19, 20, we have selected this 
lid in combination with the 100 µm thick microwell membrane (M5) for the preparation of the sealed device. 
Figure 5C shows the stimulation index for the islets encapsulated there in comparison to free-floating islets from 
two different donors. The sealed islets produce and release insulin upon stimulation after one day of culture and 
they remain functional, indicating also their viability after 7 days of culture. Interestingly, during the 7 days’ 
culture period, they show an increase in performance comparable to the increase observed for the free-floating 
islets. The encapsulated islets respond to glucose concentration changes independent on the donor variability, 
although they secrete significantly lower amount of insulin in comparison to free-floating islets (Supplemental 
Figure 1) (p < 0.05).
Figure 4. MIN6 aggregates functionality. (A) A comparison of MIN6 aggregates insulin secretion detected on 
the top and bottom compartment separately, in an open transwell system using untreated microwell membranes - 
 M1 and microwell membranes after 2 h treatment with NaClO solution - M2, (B) Total insulin secretion of 
MIN6 aggregates over 5 h using final open construct with microwell membranes after 24 h of treatment with 
NaClO solution - M3; Insulin secretion is normalized to the first low glucose stimulation and presented as a 
stimulation index. Error bars indicate standard deviation (n = 3), **p < 0.05.
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Discussion
In this study, we propose a novel membrane-based islet macroencapsulation device. We developed a sealed device 
that consists of a microwell membrane for hosting the islets and a flat membrane as a lid. Our device was devel-
oped using non-degradable polymer blend of PES/PVP15, 21. PES is an excellent membrane forming material with 
very good chemical and mechanical properties therefore it has been widely used in medical devices, artificial 
organs and blood purification processes, such as hemodialysis membranes22–25. PVP forms uniform blend with 
PES due to strong donor/acceptor interaction between O=CN functional groups from PVP and O=S=O from 
the benzene ring during membrane formation. By blending PES with PVP, we can obtain a more hydrophilic 
material with better biocompatibility26, 27, low fouling and non-cell adhesive properties28, 29. All these properties 
are essential for preventing islet clustering and attachment, and increase islet survival after transplantation18, 30, 31.
The microwell membranes were fabricated using PSµM method15, 21. Through immersion precipitation of 
the polymer on a micropatterned mold, we obtained in one step a highly porous material with controllable 
micrometer-scale pores having excellent quality microwells (see Fig. 4). Recently, Buitinga et al.14 developed an 
open poly(ethylene oxide terephthalate)-poly(butylene terephthalate) (PEOT/PBT) microwell scaffold fabricated 
by microthermoforming, where heated polymer porous film was stretched into a negative mold in order to obtain 
similar microwells. The microthermoforming method, however, affects pore morphology causing stretching and 
collapsing thus can have a negative effect on transport properties. Important advantages of PSµM applied here 
is the fabrication of a porous microstructured membrane in one step and the easy upscaling. The fabrication 
parameters can be tuned to control material shrinkage and obtain the suitable pore size, adequate porosity and 
interconnectivity of the microwells membranes, all very important for sufficient transport of nutrients to the 
encapsulated islets. In our device, the membrane porosity is carefully tailored to allow glucose diffusion to the 
islet and corresponding insulin release in response to blood glucose levels. The selective layer of the microwel 
Figure 5. Human islets encapsulation. (A) Islets viability after 1 day of culture in closed system with M3 
microwell membrane, green-live cells, red-dead cells, (B) Islets functionality using a closed system with various 
porosities of the lid and various thickness of microwell membranes: 250 µm thick microwell membrane after 
24 h treatment – M3 and 100 µm thick microwell membrane after 24 h treatment – M5, (C) Functionality of 
islets from two donors over 7 days using a sealed device. To compare response to glucose concentration changes 
of islets from two donors, the insulin secretion is normalized to the first low glucose stimulation and presented 
as a stimulation index. Error bars indicate standard deviation (n = 3), **p < 0.05.
www.nature.com/scientificreports/
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membrane is microporous (1–3 µm) and therefore is expected to block the immune cells (size of ~10 μm12) and 
can provide sufficient immune isolation for encapsulated islets (see supplemental Fig. 2). Additionally, the device 
avoids aggregation of the islets, since they are seeded on separated microwells. According to the modeling studies 
of Dulong and Legallais32, in order to increase the number of functional islets, a higher islet density needs to be 
used. However, high islet density with no cell aggregation would require the application of a gel system to keep the 
islets separated leading to the need of large devices, almost impossible to apply in humans. Our microwell device 
prevents islet aggregation thereby improving their chances of survival and function, since separation allows for a 
proper supply of nutrients and oxygen to all islets. The dimensions of the microwells (500 × 400 um) are suitable 
for fitting the broad range of pancreatic islets obtained after islet isolation. Lehmann et al.18 describe the superior-
ity of small islets over large ones due to higher survival in both normoxic and hypoxic conditions and better insu-
lin secretion indicating that optimal mass transport plays an important role. Islets with a diameter around 150 µm 
are recommended for encapsulation in order to avoid necrosis, which usually occurs in larger islets33. Using our 
fabrication method, it is possible to create membranes containing microwells with smaller dimensions to accom-
modate a population of smaller diameter islets, or pseudoislets created from stem cell derived de novo beta cells, 
thereby further increasing beta cell survival and function. This is one of the main goals of a follow up study.
Clark et al.34 proposed heat-sealing as an effective method to close polysulfone hollow fiber membranes in 
order to prevent cell infiltration. Here, we applied heat sealing only on the edges of the membranes to prevent sur-
face damage, and preserve pore morphology and porosity, which are important for adequate transport properties. 
Our device also features a practical small inlet, which makes islet seeding quite simple. After seeding, the islets 
settle on the bottom of the wells and remain stable during further handling procedures.
The pore size of the lid membrane is 0.45 µm, in agreement with other studies, which have shown that this pore 
size does not allow host cells to permeate to the device providing protection to allogeneic and xenogeneic trans-
plants19, 20, 35, 36. For comparison, the TheraCyteTM system, is composed of a cell impermeable 0.4 µm pore mem-
brane laminated to a 5 µm outer membrane for support and tissue integration12. Besides, Cell Pouch SystemTM - a 
biocompatible polymeric macrocapsule, mimicking natural environment in the host for encapsulated pancre-
atic cells contains large pores to allow the development of fibrous tissue rich in vessels without immunoprotec-
tion whereas the “Islet sheet” macroencapsulation system consists of flat, thin alginate sheets in which islets are 
entrapped without efficient islet separation37, 38.
In order to evaluate the function of our device, we used MIN6 insulin secreting cells, which are able to cre-
ate stable aggregates and mimic pancreatic islet function39. These aggregates function when seeded in the open 
250 µm thick microwell membranes (M1). By tuning the membrane porosity (via partly washing PVP with 
NaClO) we obtained membranes with optimal diffusion of insulin (M2). In fact, the concentration of insulin, 
which passes through the membrane equalizes after 30 minutes to the one above the membrane, where cells in the 
microwells are in direct contact with the glucose solution, showing that insulin secreted by the beta cells can be 
transported relatively unhindered across the membrane. When using microwell membranes with 5 times higher 
water permeability (M3) than the original membrane (M1), pseudo-islets seeded in the membrane functioned 
well (stimulation index above 2), although the stimulation indexes were lower than in case of free-floating aggre-
gates. Wienk et al.40 first reported an increase in water permeability of PES/PVP membranes attributed to PVP 
degradation and leaching during membrane treatment with a NaClO solution. This observation was also later 
confirmed by other researchers28, 41, 42. Here, the membrane treatment with NaClO allowed increase of membrane 
porosity and optimization of the membrane transport properties, however, at the same time not all PVP was 
removed so the membranes have still low fouling and low adhesive properties (see Fig. 4).
Islets encapsulated in our closed system using 100 µm thick microwell membrane (hydraulic permeability 
3845 [L/m2/h/bar]) maintain their glucose responsiveness comparable to free-floating islets, regardless of the 
porosity of the membrane lid. This fits well with the results of literature studies which indicate that when the dif-
fusion distance of cells to nutrients is lower than 200 μm, cell survival could be improved12, 43. Besides, our results 
confirm that decreasing membrane thickness, thereby reducing the distance that molecules such as glucose and 
insulin would need to travel through the membrane, has also a positive effect on islet functionality. Moreover, 
islets response to glucose concentration changes was improved after longer culture for 7 days (stimulation index 2 
times higher for high glucose stimulation in comparison to day 1). Due to isolation and handling procedure islets 
are exposed to cellular stresses, therefore their functionality might be affected during first day of in vitro culture. 
However islet culture for longer period allows for their recovery and results in improved their functionality.
In comparison to other devices reported in the literature, our device combines two important characteristics: 
it avoids aggregation of the islets, since they are seeded on separated microwells, and is expected to protect them 
from the host immune cells via the tailored membrane porosity. It is finally important to note here that the devel-
oped membranes are mechanically stable and all the above steps can be performed without problems. Preliminary 
implantation studies in mice (results not shown) indicated that the device can be easily implanted and retrieved.
Conclusions and Outlook
In this study, we have developed a novel PES/PVP device for macroencapsulation, in which islets are physically 
separated in microwells and closed by a membrane lid, without compromising their function. Non-degradable 
PES/PVP membranes are mechanically stable and can offer long-term protection of encapsulated islets. Moreover, 
low adhesive material properties combined with our specific microwell design prevent islet spreading and aggre-
gation. Additionally, the tailored membrane porosity allows for sufficient glucose and insulin transport, crucial 
for maintaining islet viability and function.
This study showed the proof of concept of applying microwells membranes for islets encapsulation. We 
designed membranes with microwells of 500 µm in diameter in order to fit the broad size range of islets available 
for us. Since for clinical implementation, small size islets (50–150 μm) which show higher viability and func-
tion comparing to bigger islets18 should be used, in the future, we will fabricate membranes with smaller wells 
www.nature.com/scientificreports/
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(diameter of 200 µm) and with smaller spacing between the wells (50 µm). It is generally perceived that around 
540000 islets should be sufficient to restore normoglycemia in a patient of 70 kilograms44. Based on this, we esti-
mate that we would need 4 of those membranes with diameter of 10 cm in order to encapsulate clinically relevant 
number of islets. Besides, the thin film design of our device allows the creation of multilayer stacks of microwell 
membranes similar to those developed in our laboratory recently for upscaling of tissue engineering constructs45, 
enabling possibly the development of one compact microwell device.
Materials and Methods
Microwell membrane fabrication. Microwell membranes were fabricated using phase separation micromolding 
(PSµM)15–17. For this, we used a polymer blend of 15 wt.% poly(ethersulfone) (PES) (Ultrason, E6020P) and 
5 wt.% polyvinylpyrrolidone (PVP) (MW = 40000, Sigma Aldrich) in N-Methylpyrrolidone (NMP) (Acros 
organic). This polymer solution was stirred on a roller bank overnight, at room temperature. The membranes 
were prepared by casting the solution on a custom made, silicon, micropatterned mold with spatially organized 
dome-like structures of 500 µm height and 500 µm in diameter presented on Fig. 6.
A custom-made casting machine, with micrometric screws to regulate the casting thickness, was used to 
obtain 100 µm and 250 µm thick membranes. Casting was followed by immersion into a coagulation bath, con-
taining demineralized water. After the polymer solution became turbid and precipitated, the membranes were 
removed from the mold, rinsed with demineralized water in order to remove remaining solvent traces and stored 
in demineralized water till further use. In order to increase the membrane porosity, the membranes were treated 
with 4000 ppm sodium hypochlorite aqueous solution (NaClO, Fluka) for either 2 h or 24 h. Subsequently, the 
membranes were washed and stored in demineralized water.
Scanning electron microscopy. For scanning electron microscopy (SEM), the membranes were dried 
overnight in air at room temperature and cryogenically broken in liquid nitrogen when needed for cross section 
images.
Microwell membranes with cells were fixed in 4% paraformaldehyde for 1 h at room temperature, dehydrated 
in water-ethanol solutions following a gradient (volume ratio water: ethanol of 100:0, 50:50, 25:75, 10:90, 5:95 
and 0:100) and dried after dipping in hexamethyldisilizane overnight. Dried membranes were placed on the SEM 
holders and sputter-coated with nm-thick gold layer prior to imaging.
Cell culture and controlled cell aggregate formation. MIN6-B1 mouse insulinoma cells (kindly pro-
vided by Dr. P. Halban, University Medical Center, Geneva, Switzerland) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Gibco) supplemented with 10% (v/v) FBS (Lonza), 100 U/mL penicillin and 100 mg/mL 
streptomycin (Gibco) and 70 µM freshly added beta-mercaptoethanol (Gibco) at 37 °C and 5% CO2.
Sterile agarose microwells were fabricated as described previously46. In short, polydimethylsiloxane (PDMS) 
negative molds carrying 200 µm pillars were sterilized with 70% ethanol. 3% UltraPureTM agarose (Gibco) was 
dissolved in PBS. The solution was heated to 100 °C in a microwave oven. Molds were placed inside a 6-well plate 
Figure 6. Silicon micropatterned mold. (A) Top view. (B) Side view.
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and filled with 8 mL of 3% agarose solution. The plates were centrifuged at 300 g for 1 min to remove air bubbles 
and stored at 4 °C for at least 30 min. After the gel was formed, the molds were gently removed from the agarose 
using a sterile spatula. Using a sterile punching device, chips were punched out leaving a thin agarose wall on all 
sides to fit into a 12-well plate. Stable pseudo-islets were then prepared based on the work of Hilderink et al.47: 
MIN6 cells were then seeded onto the agarose chips (250 cells per pseudo-islet). The plates were centrifuged at 
150 g for 1 min and 2 mL of medium was carefully added to the chips. Medium was refreshed 24 h after seeding. 
After 48 h at 37 °C, aggregates (80–100 µm in diameter) were flushed out of the chips and used for seeding on the 
microwell structured membranes.
Human islets of Langerhans isolated from 3 donor pancreata (purity 85%, 85% and 75% respectively) 
were provided by the Human Islet Isolation Laboratory at the Leiden University Medical Center (Leiden, The 
Netherlands). Studies were only performed on islets that could not be used for clinical transplantation and for 
which research consent was available, according to national laws. The islets were cultured in CMRL 1066 medium 
(5.5 mmol/L glucose) containing 10% FBS, 2 mM GlutaMAX, 100 mU/mL penicillin and 1 mg/mL streptomycin 
(Gibco), 10 mmol/L HEPES, and 1.2 mg/mL nicotinamide.
Membrane transport properties: water permeability and insulin, glucose diffusion. Microwell 
membranes with an effective surface area of 0.9 cm2 were used for clean water flux measurements. The experi-
ments were performed at room temperature using nitrogen pressurized dead-end ‘Amicon type’ ultrafiltration 
cell and MiliQ water. Firstly, the membranes were pre-pressurized for 30 minutes at 0.7 bar. Afterwards, the clean 
water flux through the membranes at various transmembrane pressures was measured for at least 20 minutes. The 
membrane hydraulic permeability was calculated from the slope of the linear part of the flux versus the trans-
membrane pressure relation.
In order to determine the diffusion coefficient of insulin and glucose through the microwell membranes, a 
two-compartment transwell system was used. The commercial membrane was removed from the Transwell insert 
(Corning) and a ‘sealing’ poly ether ether ketone (PEEK) ring was fabricated to seal the microwell membrane to 
the insert (Fig. 7A). The assembled Transwell insert was placed in the well plate, creating top and bottom com-
partments separated by the microwell membrane. The membranes were sterilized in 70% ethanol, washed with 
PBS and pre-incubated in culture medium. Modified Krebs buffer (115 mM NaCl, 5 mM KCl, 24 mM NaHCO3, 
Sigma) supplemented with 2.2 mM CaCl2, 20 mM HEPES (Gibco), 30% bovine serum albumin, 1 mM MgCl2, and 
0.1 mM Theophylline (Sigma) was prepared at pH 7.448. From this Krebs buffer, a high (16.7 mM) glucose solution 
was prepared. For the glucose diffusion experiment, the top compartment of the transwell system contained the 
prepared buffer, whereas the bottom compartment contained glucose solution. In the case of insulin diffusion 
experiment, a 50 µg/L insulin in glucose solution was prepared and put in the top compartment, while the bottom 
compartment contained the earlier prepared buffer. After 1 hour, samples were collected separately from both 
compartments (n = 6).
In order to evaluate whether the membrane limits the response to glucose concentration, 150 MIN6 pseudo 
islets were seeded on the top of the microwell membrane. Subsequently, the medium was replaced by the premade 
Figure 7. Experimental setup. (A) Schematic representation of two-compartment transwell system, (B) 
Schematic overview of the custom made sealing machine. Two Teflon coated heating elements with a circle with 
a small opening were used to obtain a seal between the microwell membrane and the PES lid, (C) The sealed 
device.
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buffer on the top compartment and glucose solution on the bottom compartment. In response to glucose diffus-
ing through the membrane to the top compartment, the MIN6 aggregates there secreted insulin. During a period 
of 1 hour, samples were taken separately from the top and bottom compartment every 10 minutes. The samples 
were analyzed for glucose concentration using a Vitros DT60 chemistry system and insulin concentration using a 
Mouse ELISA immunoassay (Mercodia). The amount of glucose and insulin that passes through the membrane, 
from the donor compartment to the acceptor compartment, in time, indicates whether the porosity of the mem-
brane is optimal for transport of these molecules. The permeability of glucose and insulin through the membranes 
was calculated using the equation:
permeability m s flux gm s
C g m
l m( ) ( )
( )
( )
(1)
2 1
2 1
3= ∆
×−
− −
−
where, ΔC is the concentration difference between the donor and the acceptor compartment and l is the geomet-
rical thickness of the membrane. Flux was calculated using the equation:
=− −
−
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where, Cacceptor is the glucose or insulin concentration in the acceptor compartment, Vacceptor is the volume of the 
acceptor compartment and A is the surface area of the membrane. From the permeability coefficient, we calcu-
lated the diffusion coefficient using equation 3:
diffusion coefficient m s permeability m s
K
( ) ( ) (3)
2 1
2 1
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where K is the partition coefficient of glucose and insulin in the membrane, which was considered to be equal to 
one.
MIN6 aggregates functionality in vitro using open system. The membranes for cell seeding were 
placed in the transwell system (Fig. 3A), sterilized with 70% ethanol for 30 min and washed 3 times in PBS. 150 
MIN6 aggregates in 300 µl of medium were seeded on the top of the microwell membranes and 300 µl of medium 
was added to the bottom compartment. After 1 day of culture, a glucose induced insulin secretion test (GIIST) 
was performed, with free-floating pseudo-islets in a commercial transwell system (MilliPore), as a control. The 
modified Krebs buffer was prepared as previously described and was used to prepare low (1.67 mM) and high 
(16.7 mM) glucose concentration solutions. Both the free-floating pseudo-islets and the microwell membranes 
with MIN6 aggregates were washed three times (5 min) in the Krebs buffer, followed by a pre-incubation of 
90 min in the low glucose concentration buffer. All samples were then incubated for 60 min in subsequent low, 
high and low glucose concentration buffer with three times 5 min washing in the Krebs buffer, between each high 
and low. The final function test was performed with additional high and low glucose concentration buffer incu-
bation. During the test, both top and bottom compartments of the transwell system contained the same buffer for 
each step respectively. Samples were taken after each incubation time, spun down (300 g, 3 min) and the superna-
tant was stored at −20 °C. Samples were analyzed using insulin Mouse ELISA immunoassay (Mercodia) accord-
ing to the manufacturer’s instructions. The functionality of MIN6 aggregates was determined by the stimulation 
index that is defined as the insulin secretion when stimulated with the first low glucose buffer.
Human islets viability in closed system. The closed microwell system (see details about its preparation 
in the next section), containing 150 human islets, was opened after 1 day of culture and live/dead analysis was per-
formed in order to examine cell viability. Membranes with islets inside the wells were placed in a solution contain-
ing 0.25 µl/mL calcein (green) and 3 µl/mL ethidium homodimer (red) in PBS and incubated for 30 min at 37 °C 
in the dark. Green-fluorescent (ex 494 nm/em 517 nm) live cells and red florescent (ex 517 nm/em 617 nm) dead 
cells were imaged using an EVOS digital inverted fluorescence microscope and photomicrographs were taken.
Human islets functionality in vitro. Closed system. A closed system containing a microwell membrane 
covered with a flat PES membrane lid was developed. For the lid, we investigated membranes with two different 
porosities (0.45 µm and 5 µm, Sterlitech). These membranes were sterilized with 70% ethanol for 30 min, washed 
3 times in PBS and pre-incubated in culture medium overnight. Afterwards, the microwell membrane was assem-
bled within the transwell system and human islets (150) in 300 µl of medium where seeded on the top. Medium 
was carefully aspirated, leaving the islets inside the wells of the membrane. The insert was removed while the 
microwell membrane with islets remained within the sealing ring. The lid was placed on the top of the microwell 
membrane and the system was sealed with the insert fitted in the sealing ring.
Sealed device. A sealed device was designed with the aim of implantation. The microwell membrane and the 
flat lid membrane were placed between the two shaped molds of a custom-made sealing machine (Fig. 7B,C). A 
temperature of 90 °C was applied for 10 seconds and the membranes were sealed on the edges, leaving open the 
middle part and a small inlet for cell seeding. The sealed device was sterilized with 70% ethanol, washed in PBS 
and pre-incubated in culture medium overnight. The islets in 10 µl of medium were seeded inside the device 
via the small inlet, which was closed after seeding using sterile, surgical staples (Teleflex Medical, HORIZON, 
Ligating clips).
To assess the encapsulated islets’ function, a glucose induced insulin secretion test (GIIST) was performed 
after culturing them statically for 1 day and 7 days. Free-floating islets in transwell system (MilliPore) (n = 3) 
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were used as a control. Islets were first pre-incubated in modified Krebs buffer (115 mM NaCl, 5 mM KCl, 24 mM 
NaHCO3, 2.2 mM CaCl2, 20 mM HEPES, 1 mM MgCl2, 2 mg/mL bovine serum albumin, pH 7.4) for 90 min at 
37◦C and 5% CO2. All samples were then stimulated for 1 hour in subsequent low (1.67 mM), high (16.7 mM), 
low, and again high and low glucose buffer with three times 5 min washing in the Krebs buffer between the high 
and low glucose incubation step. Samples were taken after each incubation, spun down (300 g, 3 min) and the 
supernatant was stored at −20 °C. Samples were analyzed using an insulin ELISA (Mercodia). The functionality of 
human islets was determined by the stimulation index, which is defined as the insulin secretion after stimulation 
with high glucose buffer relative to the insulin secretion when stimulated with the first low glucose buffer. Islets 
with stimulation index higher than two were regarded functional.
Statistical analysis. Results are presented as the mean ± standard deviation. Statistical analyses were 
performed using two-tailed analysis of variance (ANOVA) using SPSS Statistics software (version 24, IBM 
Corporation) to compare the insulin concentration and stimulation indexes upon glucose stimulation for MIN6 
aggregate and islets seeded within various microwell membranes. Statistical significance was considered at 
p- values < 0.05.
Data availability. The datasets generated and analyzed during the current study are available from the cor-
responding author on reasonable request.
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